Enveric Biosciences, Inc. (ENVB) Stock Profile — Insider Trades & Financials

Net Income-$2.2M

EPS$-35.74

Market Cap$3.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Joseph Tucker

CEO & Executive Director

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

Founded: 1994
Employees: 6
Headquarters: Cambridge, Massachusetts, United States

⚡

Core Efficiency

ROE?

-52.52%

ROA?

-43.06%

📊

Profitability Ratios

Current Ratio?

5.38

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 20, 2026 (in 164 days)

Annual Report (10-K) — Based on filing pattern

Sep 20, 2026

Predicted10-K

Mar 27, 2026

10-KQ4 20253d after period end

Mar 27, 2026

10-KFY 202586d after period end

Nov 14, 2025

10-QQ3 20252d after period end

Aug 14, 2025

10-QQ2 20251d after period end

May 14, 2025

10-QQ1 20250d after period end

Mar 28, 2025

10-KQ4 20241d after period end

Mar 28, 2025

10-KFY 202587d after period end

Nov 14, 2024

10-QQ3 20242d after period end

Loading company sections...

Enveric Biosciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness